Antibody Therapeutics Market

The report "Antibody Therapeutics Market by Product (Commercial, Pipeline), Format (mAb, ADC, Fragment), Target (PDL1, Cytokine), Therapy area (Oncology, Neurology, Inflammatory), Source (Human, Humanized), RoA (IV, SC), Region, Competition - Global Forecast to 2035", is projected to grow from USD 311.2 billion in 2026 and to reach USD 597.1 billion by 2035, at a Compound Annual Growth Rate (CAGR) of 7.5% during the forecast period.

Browse 400 market data Tables and 55 Figures spread through 400 Pages and in-depth TOC on "Antibody Therapeutics Market by Product (Commercial, Pipeline), Format (mAb, ADC, Fragment), Target (PDL1, Cytokine), Therapy area (Oncology, Neurology, Inflammatory), Source (Human, Humanized), RoA (IV, SC), Region, Competition - Global Forecast to 2035"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/antibody-therapeutics-market-178852478.html

The antibody therapeutics market is experiencing significant growth, driven by the increasing use of monoclonal antibodies and other antibody-based therapies across oncology, autoimmune disorders, inflammatory diseases, and other chronic conditions. Market expansion is further supported by rapid technological advances in antibody engineering, including bispecific antibodies, antibody-drug conjugates (ADCs), Fc optimization, and improved antibody design platforms.

By format, the monoclonal antibodies accounted for the largest share of the market in 2025. 

By format, the antibody therapeutics market is categorized into monoclonal antibodies, polyclonal antibodies, antibody fragments, bispecific antibodies, and ADCs. In 2025, the monoclonal antibodies segment accounted for the largest share of the market, supported by its large, approved product base, broad clinical use, and strong commercial adoption across oncology, autoimmune diseases, inflammatory disorders, infectious diseases, and other chronic conditions.

In 2025, the hospitals & specialty care centers segment accounted for the largest share of the antibody therapeutics market.

By end user, the antibody therapeutics market includes hospitals & specialty care centers, long-term care facilities, and other end users. In 2025, the hospitals & specialty care centers segment accounted for the largest share of the market. The growth of the hospitals & specialty care centers segment is attributed to the increasing use of antibody therapeutics across oncology, autoimmune diseases, inflammatory disorders, ophthalmology, and rare diseases. These facilities play a critical role in administering complex biologics such as monoclonal antibodies, bispecific antibodies, ADCs, and other next-generation antibody formats that often require specialist supervision, infusion or injectable delivery, and close patient monitoring.

By region, North America accounted for the largest share of the market in 2025.

In 2025, North America accounted for the largest share of the antibody therapeutics market, owing to the presence of strong regional players with advanced manufacturing capabilities and robust supply-chain networks. These companies benefit from product approvals under supportive regulatory frameworks implemented by the US FDA and Health Canada. Product commercialization and innovation are the primary catalysts for growth in the region's expanding pharmaceutical & biotechnology industry. Partnerships and investments with academic & research centers to scale up production are also expected to be growth drivers for this regional segment.

Leading players in the antibody therapeutics market include AbbVie Inc. (US), Merck (US), Novartis AG (Switzerland), Bristol-Myers Squibb (US), Johnson & Johnson (US), F. Hoffmann-La Roche Ltd. (Switzerland), Sanofi (France), Amgen Inc. (US), Regeneron Pharmaceuticals Inc. (US), and Boehringer Ingelheim International GmbH (Germany), among others.

Don’t miss out on business opportunities in Antibody Therapeutics Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com